Callyope, an EIC Accelerator Winner, Listens for Relapse in Speech

Psychiatry still measures most symptoms by asking: a clinician's interview, a patient's questionnaire, an appointment weeks apart. Callyope, a start-up registered in May 2022 west of Paris, is building software that listens instead. Its pitch, repeated in a September 2025 announcement by the Alzheimer's Drug Discovery Foundation and an interview with pharmaphorum in June 2026, is that about 30 seconds of speech is enough for its model to assess mood, psychotic and cognitive symptoms.

The EIC Accelerator selected the company's project, CALLYOPECOPILOT, at the 1 October 2025 cut-off for blended finance. CORDIS records a grant agreement signed on 29 May 2026 with an EU contribution of €2,498,053.25, running from 1 June 2026 to 31 May 2028, under the GenAI4EU challenge for generative AI. Five months into a 24-month project, this article sets out what the company promised and what can already be checked.

What the software does

Callyope's patients record short voice answers in an app, or a nurse records a call, and the model analyses both how they speak and what they say. TechCrunch reported in November 2023 that the system looks for features tied to specific conditions, such as disorganised speech in schizophrenia and accelerated speech in bipolar disorder, and combines them with sleep and activity data to alert clinicians. The CORDIS objective describes the EIC project as the first speech foundation model specialised in mental health, used to summarise clinical cases, run transdiagnostic assessments and estimate relapse risk in depression, bipolar disorder and schizophrenia.

The company's website now splits the offer into clinical documentation (chart reviews, an ambient scribe and document drafting, the last marked as coming soon) and symptom monitoring (voice analysis and validated questionnaires). The voice analysis side is the one the EIC project describes.

The company's own figures differ between its pages. The AWS case study says the model was trained on 20,000 speakers across 10 brain illnesses and 7 languages, and that eight clinical trials with 1,000 patients are under way. Its Google for Startups profile gives seven clinical studies with more than 1,000 patients and 2,000 controls, and says one minute of speech plus phone sensor and medical data is needed, not 30 seconds. None of these figures is independently audited.

The published evidence

The main peer-reviewed result is a study in the Journal of Medical Internet Research of 31 October 2024, led by Rachid Riad with Martin Denais and Xuan-Nga Cao among the authors. It recorded 865 healthy adults answering how they felt and how they had slept, and compared a speech model's predictions with standard questionnaires. Per the abstract indexed in Europe PMC, the best model reached an AUC of 0.76 for depression on the PHQ-9 and 0.78 on the Beck Depression Inventory, 0.77 for anxiety, 0.73 for insomnia and 0.68 for fatigue, with F1 scores between 0.49 and 0.88. The authors also report that the models were consistent across sexes but less so across education levels and worst across age groups.

Two limits matter for the EIC project. The study population was the general public, not psychiatric patients, and it measured symptoms at one point in time, not relapse. A separate September 2024 preprint by the same team reports state-of-the-art depression detection on the public Androids dataset; it has not been peer-reviewed.

The hospital trials

In October 2024 Callyope and GHU Paris psychiatrie et neurosciences, the Paris psychiatric hospital group, announced a framework agreement for scientific collaboration, which Santé mentale reported gives the company privileged access to an active file of 60,000 psychiatric patients. The first study, ObservSpeech, is registered as NCT06613334, sponsored by Centre Hospitalier Sainte-Anne. It started on 4 October 2024, plans to enrol 200 people with schizophrenia, compares voice recordings from the Callyope app with blood levels of antipsychotic drugs over six months, and was still recruiting at its last update on 21 September 2026, with primary completion estimated for April 2027.

A second trial, on anticipating depressive and manic episodes in bipolar disorder, was first posted on 23 December 2025 with 170 planned participants, weekly voice interviews in the Callyope app and an estimated primary completion in May 2027. Its listing on Veeva's trial site shows it as not yet enrolling.

The CE mark the project promises

CORDIS lists Class IIa CE marking as software as a medical device for major depression, bipolar disorder and schizophrenia as one of the project's aims. Under the EU Medical Device Regulation, a Class IIa product needs a notified body's assessment, while most Class I products are self-certified by the manufacturer. The company's website currently describes CallyoCare as a Class I medical device, and the Google for Startups page says the tool is a medical device available to clinicians. No CE certificate for a Class IIa product could be found on the company's pages or in the news coverage searched.

1. Speech model for mental health symptomsIn usePlatform described as launched in the AWS case study; general-population accuracy in JMIR.
2. Relapse risk prediction in patientsTrials openObservSpeech recruiting; bipolar study first posted December 2025.
3. Validation in several languagesNot shownThe company cites 7 training languages; no multilingual validation is published.
4. Class IIa CE markingPendingNo certificate found; the website lists a Class I device.

The money

The only equity round found in the coverage searched is Callyope's €2.2 million seed of November 2023, co-led by 360 Capital and Bpifrance's Digital Venture fund, with No Label Ventures and angels, reported by TechCrunch and FrenchWeb; FrenchWeb names Owkin's Thomas Clozel and Sorare's Adrien Montfort among the angels. 360 Capital still lists Callyope as a current portfolio company. The award was for blended finance, but no EIC Fund investment in Callyope could be found in a web search on 4 November 2026; CORDIS records only the grant.

The register shows the company's capital growing from €30,000 at registration to €45,172.40 in July 2023 and €57,959.10 after a capital increase dated 2 June 2026, four days after the grant was signed, per societe.com. Who subscribed to that increase is not public. For 2025, the French government's company search service lists revenue of zero and a net loss of €213,403; societe.com shows the same loss and marks revenue as not communicated. societe.com shows no collective insolvency procedure, and both sources list the company as active.

Where it fits in EU policy

The Commission's comprehensive approach to mental health of 7 June 2023 put the cost of mental ill-health in the EU at €600 billion a year and committed €1.23 billion to 20 flagship initiatives, as also reported by The Brussels Times. The €600 billion figure is the one Callyope's CORDIS objective cites. The EIC placed the project under GenAI4EU, its challenge for European generative AI, and the AWS case study says the company runs its model training on AWS, while its Google for Startups profile lists Google Cloud and Google's Gemma models among the tools it uses. The website states French health data hosting certification (HDS) and ISO 27001.

Callyope was not asked for comment for this article. The reporting is based on publicly available sources, listed below.